Biogen (BIIB) Equity Ratio (2009 - 2026)

Biogen (BIIB) has reported Equity Ratio for 18 consecutive years, with 0.63 the latest figure, recorded in Q1 2026.

• In Q1 2026, Equity Ratio rose 4.45% year-over-year to 0.63; the TTM figure through Mar 2026 stood at 0.63 (up 4.45% YoY), while the FY2025 annual figure was 0.62, up 4.06% from the prior year.
• Equity Ratio came in at 0.63 for Q1 2026 at Biogen, up from 0.62 in the prior quarter.
• The five-year high for Equity Ratio was 0.63 in Q1 2026, with the low at 0.0 in Q3 2025.
• Average Equity Ratio over 5 years is 0.53, with a median of 0.57 recorded in 2024.
• Across the five-year window, Equity Ratio gained 21.53% in 2023 and plunged 99.69% in 2025, its largest moves.
• Year by year, Equity Ratio stood at 0.55 in 2022, then climbed by 1.11% to 0.55 in 2023, then climbed by 8.1% to 0.6 in 2024, then grew by 4.06% to 0.62 in 2025, then advanced by 2.01% to 0.63 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.63, 0.62, and 0.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.